INTRODUCTION: Research on the deposition of mainstream smoke particulate in the respiratory tract of smokers is needed to understand how exposure may vary based on cigarette menthol content. METHODS: We conducted a nine-participant crossover study in which smokers were randomly assigned to cigarettes differing primarily in menthol content. Participants smoked the test cigarettes ad libitum for one week, provided spot urine samples, and then smoked four test cigarettes in a laboratory session; this was repeated for the other test cigarette in week two. Fine and ultrafine particulate matter in exhaled breath were characterized, and smoking behavior was monitored. Participant-specific mainstream smoke, generated using each participant's topography data, was characterized. During home smoking, participants collected their spent test cigarette butts for estimates of mouth-level exposures (MLE) to mainstream nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). RESULTS: Participant-specific mainstream smoke NNK was higher (39%) and daily MLE to NNK was also higher (52%) when participants smoked the menthol cigarette. Nicotine was not significantly different. Participants retained more ultrafine particulate (43%) and fine particulate benzo(a)pyrene (43%) when smoking the menthol cigarette. There were no significant differences in the levels of urinary biomarkers for nicotine, NNK, or pyrene. CONCLUSION: This study demonstrates the use of noninvasive real-time techniques to measure exposure differences between cigarettes differing primarily in menthol content. Differences between NNK exposure, ultrafine particle and benzo(a)pyrene deposition, and smoking behavior were observed. Additional research using these techniques with cigarettes that differ only in menthol content is required to unequivocally attribute the exposure differences to presence or absence of menthol.
RCT Entities:
INTRODUCTION: Research on the deposition of mainstream smoke particulate in the respiratory tract of smokers is needed to understand how exposure may vary based on cigarette menthol content. METHODS: We conducted a nine-participant crossover study in which smokers were randomly assigned to cigarettes differing primarily in menthol content. Participants smoked the test cigarettes ad libitum for one week, provided spot urine samples, and then smoked four test cigarettes in a laboratory session; this was repeated for the other test cigarette in week two. Fine and ultrafine particulate matter in exhaled breath were characterized, and smoking behavior was monitored. Participant-specific mainstream smoke, generated using each participant's topography data, was characterized. During home smoking, participants collected their spent test cigarette butts for estimates of mouth-level exposures (MLE) to mainstream nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK). RESULTS:Participant-specific mainstream smoke NNK was higher (39%) and daily MLE to NNK was also higher (52%) when participants smoked the menthol cigarette. Nicotine was not significantly different. Participants retained more ultrafine particulate (43%) and fine particulate benzo(a)pyrene (43%) when smoking the menthol cigarette. There were no significant differences in the levels of urinary biomarkers for nicotine, NNK, or pyrene. CONCLUSION: This study demonstrates the use of noninvasive real-time techniques to measure exposure differences between cigarettes differing primarily in menthol content. Differences between NNK exposure, ultrafine particle and benzo(a)pyrene deposition, and smoking behavior were observed. Additional research using these techniques with cigarettes that differ only in menthol content is required to unequivocally attribute the exposure differences to presence or absence of menthol.
Authors: Marielle C Brinkman; Hyoshin Kim; Sydney M Gordon; Robyn R Kroeger; Iza L Reyes; Dawn M Deojay; Caleb Chitwood; Timothy E Lane; Pamela I Clark Journal: Nicotine Tob Res Date: 2015-09-16 Impact factor: 4.244
Authors: Cindy M Chang; Selvin H Edwards; Aarthi Arab; Arseima Y Del Valle-Pinero; Ling Yang; Dorothy K Hatsukami Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-11-09 Impact factor: 4.254
Authors: Adam B Murphy; Folasade Akereyeni; Yaw A Nyame; Mignonne C Guy; Iman K Martin; Courtney M P Hollowell; Kelly Walker; Rick A Kittles; Chiledum Ahaghotu Journal: Prostate Date: 2013-07-03 Impact factor: 4.104
Authors: Christina Vaughan Watson; Patricia Richter; B Rey de Castro; Connie Sosnoff; Jennifer Potts; Pamela Clark; Joan McCraw; Xizheng Yan; David Chambers; Clifford Watson Journal: Am J Health Behav Date: 2017-05-01
Authors: Ping-Ching Hsu; Renny S Lan; Theodore M Brasky; Catalin Marian; Amrita K Cheema; Habtom W Ressom; Christopher A Loffredo; Wallace B Pickworth; Peter G Shields Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-09-14 Impact factor: 4.254
Authors: Marielle C Brinkman; Hyoshin Kim; Stephanie S Buehler; Anna M Adetona; Sydney M Gordon; Pamela I Clark Journal: Tob Control Date: 2018-10-30 Impact factor: 7.552
Authors: Ian C MacGregor; Stephen B Stanfill; Sydney M Gordon; Douglas J Turner; Jenny M Butler; Elizabeth A Hanft; Hyoshin Kim; Robyn R Kroeger; Marielle C Brinkman; Margaret E Tefft; Pamela I Clark; Stephanie S Buehler Journal: Toxicol Rep Date: 2014-01-01